Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation
CNS Spectrums December 10, 2020 Nelson B Rodrigues, Ashley N. Siegel, Orly Lipsitz et al. 17 citations
Intravenous (IV) ketamine effectively reduces symptoms of depression, suicidal ideation, anxiety, and anhedonia in adults with treatment-resistant depression, regardless of whether they have previously undergone neurostimulation. In a retrospective analysis of 238 patients, those without prior neurostimulation experienced an average 6.4-point reduction on a depression severity scale, while those with a history of neurostimulation showed a 4.3-point reduction. No significant differences emerged between the groups, indicating that IV ketamine benefits even highly intractable patients.